Vaccines for prevention of respiratory syncytial virus infection

Research Article
Open access

Vaccines for prevention of respiratory syncytial virus infection

Lingjie Yu 1*
  • 1 Yew Wah International School of Guangzhou    
  • *corresponding author 1811411112@mail.sit.edu.cn
Published on 20 December 2023 | https://doi.org/10.54254/2753-8818/21/20230847
TNS Vol.21
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-83558-215-2
ISBN (Online): 978-1-83558-216-9

Abstract

Respiratory syncytial virus is a virus that causes infections in lower respiratory tract among infants aged under 5 years old, older adults aged above 65 years old and populations with other potential complications. Some susceptible populations to RSV may develop pneumonia and bronchiolitis. The mechanism of RSV virus transmission is through air droplets. The burden of hospitalization causes by the infection of RSV is severe and episodic, with the prevalence mainly concentrated in winter periods. The development of vaccines against RSV virus statutes in the early 1960s, but was paused and halted due to the failure of formalin inactivated vaccine. The current study first reviewed the prevalence, structure, mechanism and development history of RSV and its vaccines, following which the present work focus on a summary of the results of clinical trials of vaccines against RSV on different groups of populations, especially those with special condition, such as older adult and pregnant women.

Keywords:

RSV, infants, older adults, pneumonia, bronchiolitis, mechanism, clinical trials, formalin inactivated vaccines

Yu,L. (2023). Vaccines for prevention of respiratory syncytial virus infection. Theoretical and Natural Science,21,135-139.
Export citation

References

[1]. Nam, Hannah H., and Michael G. Ison. “Respiratory Syncytial Virus Infection in Adults.” BMJ: British Medical Journal, vol. 366, 2019, pp. 1–17. JSTOR, https://www.jstor.org/ stable/27177790. Accessed 5 May 2023.

[2]. Graham, Barney S. "The Journey to RSV Vaccines—Heralding an Era of Structure-Based Design." New England Journal of Medicine 388.7 (2023): 579-581.

[3]. Raiden, Silvina, et al. "Respiratory syncytial virus (RSV) infects CD4+ T cells: frequency of circulating CD4+ RSV+ T cells as a marker of disease severity in young children." The Journal of infectious diseases 215.7 (2017): 1049-1058.

[4]. Griffin, Marie R. "A Challenge to Respiratory Syncytial Virus Illness in Adults." New England Journal of Medicine 386.25 (2022): 2427-2428.

[5]. Turner, Tiffany L., et al. "Respiratory syncytial virus: current and emerging treatment options." ClinicoEconomics and Outcomes Research (2014): 217-225.

[6]. Englund, Janet A., and Helen Y. Chu. "Vaccines against respiratory syncytial virus: the time has come." The Journal of infectious diseases 215.1 (2017): 4-7.

[7]. Simões, Eric AF, et al. "Prefusion F protein–based respiratory syncytial virus immunization in pregnancy." New England Journal of Medicine 386.17 (2022): 1615-1626.

[8]. Wright, Peter F., et al. "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy." The Journal of infectious diseases 182.5 (2000): 1331-1342.

[9]. Karron, Ruth A., et al. "Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant." Proceedings of the National Academy of Sciences 94.25 (1997): 13961-13966.

[10]. Papi, Alberto, et al. "Respiratory syncytial virus prefusion F protein vaccine in older adults." New England Journal of Medicine 388.7 (2023): 595-608.

[11]. Falloon, Judith, et al. "An adjuvanted, postfusion F protein–based vaccine did not prevent respiratory syncytial virus illness in older adults." The Journal of infectious diseases 216.11 (2017): 1362-1370.

Cite this article

Yu,L. (2023). Vaccines for prevention of respiratory syncytial virus infection. Theoretical and Natural Science,21,135-139.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 3rd International Conference on Biological Engineering and Medical Science

ISBN：978-1-83558-215-2(Print) / 978-1-83558-216-9(Online)
Editor：Alan Wang
Conference website: https://www.icbiomed.org/
Conference date: 2 September 2023
Series: Theoretical and Natural Science
Volume number: Vol.21
ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. Nam, Hannah H., and Michael G. Ison. “Respiratory Syncytial Virus Infection in Adults.” BMJ: British Medical Journal, vol. 366, 2019, pp. 1–17. JSTOR, https://www.jstor.org/ stable/27177790. Accessed 5 May 2023.

[2]. Graham, Barney S. "The Journey to RSV Vaccines—Heralding an Era of Structure-Based Design." New England Journal of Medicine 388.7 (2023): 579-581.

[3]. Raiden, Silvina, et al. "Respiratory syncytial virus (RSV) infects CD4+ T cells: frequency of circulating CD4+ RSV+ T cells as a marker of disease severity in young children." The Journal of infectious diseases 215.7 (2017): 1049-1058.

[4]. Griffin, Marie R. "A Challenge to Respiratory Syncytial Virus Illness in Adults." New England Journal of Medicine 386.25 (2022): 2427-2428.

[5]. Turner, Tiffany L., et al. "Respiratory syncytial virus: current and emerging treatment options." ClinicoEconomics and Outcomes Research (2014): 217-225.

[6]. Englund, Janet A., and Helen Y. Chu. "Vaccines against respiratory syncytial virus: the time has come." The Journal of infectious diseases 215.1 (2017): 4-7.

[7]. Simões, Eric AF, et al. "Prefusion F protein–based respiratory syncytial virus immunization in pregnancy." New England Journal of Medicine 386.17 (2022): 1615-1626.

[8]. Wright, Peter F., et al. "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy." The Journal of infectious diseases 182.5 (2000): 1331-1342.

[9]. Karron, Ruth A., et al. "Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant." Proceedings of the National Academy of Sciences 94.25 (1997): 13961-13966.

[10]. Papi, Alberto, et al. "Respiratory syncytial virus prefusion F protein vaccine in older adults." New England Journal of Medicine 388.7 (2023): 595-608.

[11]. Falloon, Judith, et al. "An adjuvanted, postfusion F protein–based vaccine did not prevent respiratory syncytial virus illness in older adults." The Journal of infectious diseases 216.11 (2017): 1362-1370.

For authors
Guide for authors Policies for authors Aims and scope Subscription Open access policy
For editors
Policies for editors Editorial board
For reviewers
Policies for reviewers Privacy policy

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.